Two Of The Cyclos Share At Least Three Ring Carbons (i.e., Bridged) (e.g., Benzomorphans, Etc.) Patents (Class 514/295)
-
Patent number: 8242103Abstract: Bridged bicyclic sulphamides of formula (I) are disclosed for treatment of cancer.Type: GrantFiled: May 16, 2006Date of Patent: August 14, 2012Assignee: Merck Sharp & Dohme LimitedInventors: Huw David Lewis, Timothy Harrison, Mark Steven Shearman
-
Publication number: 20120183522Abstract: The present invention relates to a genus of biaryl compounds containing at least one further ring. The compounds are PDE4 inhibitors useful for the treatment and prevention of stroke, myocardial infarct and cardiovascular inflammatory diseases and disorders.Type: ApplicationFiled: March 26, 2012Publication date: July 19, 2012Applicant: DECODE GENETICS EHFInventors: Jasbir Singh, Mark E. Gurney, Alex Burgin, Vincent Sandanayaka, Alexander Kiselyov, Adalie Motta, Gary Schiltz, Georgeta Hategan, Timothy Hagen
-
Publication number: 20120172796Abstract: The present invention relates to a pharmaceutical composition for intravascular delivery of a therapeutic agent, such as paclitaxel, rapamycin, or an analog thereof. The composition includes the therapeutic agent and a biocompatible solvent, such as glycofurol. The composition can aid tissue penetration by the therapeutic agent. A catheter assembly that protects the pharmaceutical composition from the surroundings can be used for its intravascular delivery.Type: ApplicationFiled: December 29, 2011Publication date: July 5, 2012Inventor: Ralph A. Chappa
-
Publication number: 20120164191Abstract: The present invention provides methods for enhancing transmucosal uptake of a medicament, e.g., fentanyl or buprenorphine, to a subject and related devices. The method includes administering to a subject a transmucosal drug delivery device comprising the medicament. Also provided are devices suitable for transmucosal administration of a medicament to a subject and methods of their administration and use. The devices include a medicament disposed in a mucoadhesive polymeric diffusion environment and a barrier environment.Type: ApplicationFiled: March 6, 2012Publication date: June 28, 2012Applicant: BioDelivery Sciences International, Inc.Inventors: Andrew Finn, Niraj Vasisht
-
Patent number: 8193213Abstract: Hexahydroindenopyridine compounds are provided which act as spermicides and/or fungicides, spermicidal and/or fungicidal compositions containing the same, and methods for killing motile sperm and/or fungi using the compounds and compositions.Type: GrantFiled: November 25, 2008Date of Patent: June 5, 2012Assignee: Research Triangle InstituteInventors: Clarence E. Cook, Carol D. Sloan, Brian F. Thomas, Hernan A. Navarro
-
Patent number: 8193212Abstract: Methods and compositions containing huperzine are used to prevent and alleviate neuropathic pain. The invention is also directed to methods and compositions for using huperzine for the prevention and/or treatment of neuropathic pain and orthostatic hypotension.Type: GrantFiled: May 23, 2006Date of Patent: June 5, 2012Assignee: President and Fellows of Harvard CollegeInventor: Steven C. Schachter
-
Publication number: 20120107392Abstract: Methods and compositions containing huperzine are used to prevent and alleviate seizures. The invention is also directed to methods and compositions for using huperzine for the prevention and/or treatment of orthostatic hypotension.Type: ApplicationFiled: January 10, 2012Publication date: May 3, 2012Inventor: Steven C. Schachter
-
Publication number: 20120107300Abstract: Cannabinoid compositions and methods of administering said cannabinoid compositions are disclosed. The cannabinoid compositions disclosed herein include compounds which have been strategically selected to eliminate, or least mitigate, one of the negative side effects associated with consuming cannabinoids. A daytime formula includes compounds aimed at nullifying the negative side effects that cannabinoid consumption has on a patient's daily operations and activities. A nighttime formula includes compounds aimed at nullifying the negative side effects that cannabinoid consumption has a patient's sleep.Type: ApplicationFiled: November 1, 2010Publication date: May 3, 2012Inventor: Jeffrey Nathan Schirripa
-
Patent number: 8093262Abstract: Methods and compositions containing huperzine are used to prevent and alleviate neuropathic pain. The invention is also directed to methods and compositions for using huperzine for the prevention and/or treatment of neuropathic pain and orthostatic hypotension.Type: GrantFiled: May 13, 2010Date of Patent: January 10, 2012Assignee: President and Fellows of Harvard CollegeInventor: Steven C. Schachter
-
Publication number: 20110306603Abstract: 8-Substituted-2,6-methano-3-benzazocines of general structure are useful as analgesics, anti-diarrheal agents, anticonvulsants, antitussives and anti-addiction medications.Type: ApplicationFiled: August 23, 2011Publication date: December 15, 2011Applicant: RENSSELAER POLYTECHNIC INSTITUTEInventor: Mark P. Wentland
-
Publication number: 20110293640Abstract: A method of treating a subject with a cytokine-mediated inflammatory disorder comprising administering to the subject an effective amount of a pharmaceutically acceptable cholinesterase inhibitor, provided that the inhibitor is not galantamine.Type: ApplicationFiled: May 27, 2011Publication date: December 1, 2011Inventors: Kevin J. Tracey, Valentin A. Pavlov
-
Patent number: 8067455Abstract: The present invention provides a prodrug of propofol and crystalline forms thereof, methods of making the propofol prodrug and crystalline forms thereof, pharmaceutical compositions of the propofol prodrug and crystalline forms thereof, methods of using the propofol prodrug and crystalline forms thereof and pharmaceutical compositions thereof to treat diseases or disorders such as headache pain, post-chemotherapy or post-operative surgery nausea and vomiting, neurodegenerative disorders, and mood disorders.Type: GrantFiled: October 2, 2009Date of Patent: November 29, 2011Assignee: XenoPort, Inc.Inventors: Feng Xu, Mark A. Gallop, Vivek Sasikumar, Usha Dilip
-
Publication number: 20110288101Abstract: One aspect of the present invention relates to aqueous surgical compositions comprising a sigma-1 receptor agonist. Another aspect of the present invention relates to methods of irrigating ocular tissues during an ophthalmic surgical procedure such as cataract surgery. Such methods comprise bathing the ocular tissues with a composition comprising a sigma-1 receptor agonist.Type: ApplicationFiled: May 20, 2011Publication date: November 24, 2011Applicant: ALCON RESEARCH, LTD.Inventors: Lixin Wang, Marcia Danielle Ong, Chi-Chun Tsai, Michael Hartzer
-
BRIDGED BICYCLIC ARYL AND BRIDGED BICYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS
Publication number: 20110281846Abstract: Bridged bicyclic aryl or heteroaryl substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the compounds in treating diseases or conditions associated with Axl activity are also disclosed.Type: ApplicationFiled: July 26, 2011Publication date: November 17, 2011Applicant: Rigel Pharmaceuticals, Inc.Inventors: Dane Goff, Jing Zhang, Rajinder Singh, Sacha Holland, Jiaxin Yu, Pingyu Ding, Joane Litvak -
Publication number: 20110275616Abstract: Methods of utilizing an opioid agonist in a mammalian subject in a manner that inhibits peripheral effects of the opioid agonist are described. The methods comprise administering the opioid agonist in an amount sufficient to confer analgesia the subject and co-administering a neutral opioid antagonist or pharmaceutically acceptable isomorph or pharmaceutically acceptable salt thereof in an amount sufficient to substantially inhibit peripheral effects and insufficient to block substantial central effects of the opioid agonist in the subject.Type: ApplicationFiled: July 18, 2011Publication date: November 10, 2011Applicant: AIKO BIOTECHNOLOGYInventors: Wolfgang Sadée, Edward Bilsky, Janet Yancey-Wrona
-
Patent number: 8053577Abstract: A compound of Formula I, a pharmaceutically-acceptable salt or a hydrate thereof, wherein R1 is H, or C1-4 alkyl; R2 is H, halogen, or C1-4 alkyl; R3 is H, halogen, or C1-4 alkyl, and R4 is C1-6 alkyl, aryl; or ?CR3R4 is cyclopentylidene, cyclohexylidene, 1-methylpiperidin-4-ylidene, or inden-1-ylidene; R5 is independently at each occurrence F, Cl, Br, CF3, R9, OR9, NR9R10, NO2, CN, COOR9, O2CR9, CONR9R10, NR9C(O)R10, heterocyclic group, aryl, or a group of Formula II; R6 is H, halogen, or C1-4 alkyl; R7 is H, halogen, or C1-4 alkyl; R8 is H, C1-4alkyl group; R9 is H, or C1-6 alkyl; R10 is H, or C1-6 alkyl; R11 is H, or C1-4 alkyl; R12 is H, or C1-4 alkyl; m is 0, 1, or 2; when R5 is F, Cl, Br, CF3, R9, OR9, NR9R10, NO2, CN, COOR9, O2CR9, CONR9R10, NR9C(O)R10, heterocyclic group, or aryl, n is 1, 2, 3, or 4; when R5 is the group of Formula II, n is 0, 1, 2, 3, or 4; x is 0, 1, 2, 3, or 4.Type: GrantFiled: November 28, 2008Date of Patent: November 8, 2011Inventor: Hesheng Zhang
-
Publication number: 20110269791Abstract: The present invention relates to compounds defined by Formula (I), wherein the groups A, B, X, m, n and o are defined as in claim 1, possessing valuable pharmacological activity. Particularly the compounds are inhibitors of 11?-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme, such as metabolic diseases, in particular diabetes type 2, obesity and dyslipidemia.Type: ApplicationFiled: May 12, 2009Publication date: November 3, 2011Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Stefan Peters, Matthias Eckhardt, Bradford S. Hamilton, Frank Himmelsbach, Joerg Kley, Thorsten Lehmann-Lintz
-
Publication number: 20110245208Abstract: A method of combating a somatosensory disorder in a subject, comprising administering to the subject an effective amount of a composition comprising bupranolol and/or pharmaceutically acceptable derivative(s) thereof. Compositions useful for such administration are described, including salts, esters, solvates, etc. of tert-butyl[3-(2-chloro-5-methylphenoxy)-2-hydroxypropyl]amine, in which such salt, ester, solvate, etc. compound is in enantiomeric excess or homoenantiomeric in the R isomer thereof, or is formulated with racemic mixtures of the R and S stereoisomers of the salts, esters, solvates, etc. of tert-butyl[3-(2-chloro-5-methylphenoxy)-2-hydroxypropyl]amine. Combination therapy compositions of opioid receptor agonists and such compounds are also described. A method is disclosed of referential genotypic screening of candidate subjects in connection with therapeutic intervention using the compositions of the disclosure to combat the somatosensory disorder.Type: ApplicationFiled: March 30, 2011Publication date: October 6, 2011Applicant: ALGYNOMICS INC.Inventors: Luda Diatchenko, William Maixner
-
Publication number: 20110237618Abstract: The present invention relates to a method for treating, alleviating, or preventing pain, particularly migraines, functional pain syndrome, or organic pain syndrome, by administering to a patient in need thereof compound (I), or salts thereof, or pharmaceutical preparations thereof comprising mixtures of compound (I) or salts thereof with pharmaceutically-acceptable diluents wherein: R represents —NR1R2, —NHC(O)OR3, or —N?CR4R5; R1 represents H, or a C1-6 alkyl; R2 represents H, or a C1-6 alkyl; R3 represents a C1-6 alkyl, a heterocyclic group, or an aryl; R4 represents H, C1-6 alkyl, a heterocyclic group or an aryl; and R5 represents H, C1-6 alkyl, a heterocyclic group, or an aryl; or CR4R5 taken together represents a cyclolidene group.Type: ApplicationFiled: June 6, 2011Publication date: September 29, 2011Inventor: Hesheng ZHANG
-
Patent number: 8026252Abstract: 8-Substituted-2,6-methano-3-benzazocines of general structure are useful as analgesics, anti-diarrheal agents, anticonvulsants, antitussives and anti-addiction medications.Type: GrantFiled: June 3, 2009Date of Patent: September 27, 2011Assignee: Rensselaer Polytechnic InstituteInventor: Mark P. Wentland
-
Patent number: 8026251Abstract: The present invention relates to a method for treating or alleviating migraines, by administering to a patient in need thereof compound (I), or salts thereof, or pharmaceutical preparations thereof comprising mixtures of compound (I) or salts thereof with pharmaceutically-acceptable diluents wherein: R represents —NHC(O)OR3; and R3 represents methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl or phenylmethyl.Type: GrantFiled: January 26, 2008Date of Patent: September 27, 2011Inventor: Hesheng Zhang
-
Publication number: 20110230511Abstract: A compound of formula I is disclosed. Compounds of formula I are useful as analgesics, anti-inflammatory agents, anti-diarrheal agents, anticonvulsants, antitussives and anti-addiction medications.Type: ApplicationFiled: March 22, 2011Publication date: September 22, 2011Applicant: RENSSELAER POLYTECHNIC INSTITUTEInventor: Mark P. Wentland
-
Publication number: 20110230473Abstract: Disclosed herein are methods, kits and compositions for treating, preventing, inhibiting, or reducing a seizure, status epilepticus, neuropathogenesis or a neuropathology caused by overstimulation of the NMDA receptor pathway and/or exposure to an OP compound.Type: ApplicationFiled: October 9, 2009Publication date: September 22, 2011Inventors: Richard K. Gordon, Madhusoodana P. Nambiar, James C. Demar, Ruthie H. Ratcliffe, Bhupendra P. Doctor, Roberta R. Owens
-
Publication number: 20110224245Abstract: Methods and compositions containing huperzine for direct delivery to central nervous system (CNS) tissue are used to alleviate pain and for the prevention and/or treatment of seizures and epilepsy. The invention is also directed to methods and compositions for using huperzine for the prevention and/or treatment of neuropathic pain and orthostatic hypotension.Type: ApplicationFiled: September 3, 2009Publication date: September 15, 2011Applicant: President and Fellows of Harvard CollegeInventor: Steven C. Schachter
-
Publication number: 20110207763Abstract: 8-Substituted-2,6-methano-3-benzazocines of general structure I in which A is —CH2—OH, —CH2NH2, —NHSO2CH3, and Y is O, S or NOH are useful as analgesics, anti-diarrheal agents, anticonvulsants, antitussives and anti-addiction medications. 8-Carboxamides, thiocarboxamides, hydroxyamidines and formamides are preferred.Type: ApplicationFiled: May 9, 2011Publication date: August 25, 2011Applicant: RENSSELAER POLYTECHNIC INSTITUTEInventor: Mark P. Wentland
-
Publication number: 20110190262Abstract: The present invention relates to compounds defined by formula I wherein the groups R1 to R3, X, m, n and o are defined as in claim 1, possessing valuable pharmacological activity. Particularly the compounds are inhibitors of 11?-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme, such as metabolic diseases, in particular diabetes type 2, obesity and dyslipidemia.Type: ApplicationFiled: November 14, 2008Publication date: August 4, 2011Applicant: Boehringer Ingelheim International GmbHInventors: Frank Himmelsbach, Matthias Eckhardt, Bradford S. Hamilton, Armin Heckel, Joerg Kley, Thorsten Lehmann-Lintz, Herbert Nar, Stefan Peters, Annette Schuler-Metz, Matthias Zentgraf
-
Publication number: 20110150766Abstract: A transdermal patch having a top region containing an antagonist followed by a bottom region containing an agonist, whereby the bottommost end of the bottom region is secured to the skin of the patient for delivering a prescribed dosage of agonist to the patient over a predetermined period of time, the antagonist will be released by migrating or moving from the top region through the bottom region to the patient to prevent overdose. Visual indicators are provided in the patch for changing color to separately indicate the operation of the patch, delivery of prescribed dosage, and/or overdosage.Type: ApplicationFiled: February 23, 2011Publication date: June 23, 2011Inventor: Robert B. Royds
-
Publication number: 20110142939Abstract: The present invention is concerned with the use of combinations of opioid agonists and antagonists for treating Crohn's disease.Type: ApplicationFiled: September 25, 2008Publication date: June 16, 2011Inventor: Jo Bennett-Kerr
-
Publication number: 20110098265Abstract: This document provides methods and materials related to managing weight, supporting appetite control, and controlling cravings associated with smoking reduction or cessation regimens and/or nicotine reduction or cessation regimens. For example, compositions comprising an agent to support acetylcholine and an agent to support one or more biogenic amines, and methods for using such compositions for craving and appetite control are provided. Methods and materials to reduce cravings associated with the reduction or cessation of the use of chemical substances (e.g., drugs of abuse, including opioids, cocaine, methamphetamine, cannabis, alcohol), and to reduce cravings associated with addictive and/or compulsive behaviors (e.g., gambling, sex, and repetitive behaviors) are also provided.Type: ApplicationFiled: October 28, 2010Publication date: April 28, 2011Applicant: NEUROSCIENCE, INC.Inventors: Michael J. Bull, Gottfried H. Kellermann, Kelly L. Olson
-
Publication number: 20110092464Abstract: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The invention includes compositions and methods based on modulating angiotensin activity to stimulate or activate the formation of new nerve cells.Type: ApplicationFiled: December 20, 2010Publication date: April 21, 2011Applicant: BrainCells Inc.Inventors: Carolee BARLOW, Todd A. Carter, Kai Treuner, Kym I. Lorrain
-
Publication number: 20110064804Abstract: The present invention provides novel methods and compositions for the treatment and prevention of CNS-related conditions. One of the CNS-related conditions treated by the methods and compositions of the invention is Alzheimer's disease.Type: ApplicationFiled: April 9, 2010Publication date: March 17, 2011Applicant: Adamas Pharmaceuticals, Inc.Inventors: Gregory T. Went, Timothy J. Fultz
-
Publication number: 20110059905Abstract: Methods for treatment of disease-induced ataxia and non-ataxic imbalance are disclosed. The methods involve treating a patient with a compound having nicotinic acetylcholine receptor activity.Type: ApplicationFiled: March 31, 2009Publication date: March 10, 2011Inventors: Theresa A. Zesiewicz, Kelly L. Sullivan
-
Publication number: 20110034417Abstract: Novel 3,4-disubstituted-4-aryl-piperidine compounds are disclosed. Pharmaceutical compositions containing the 3,4-disubstituted-4-aryl-piperidine compounds and methods of their pharmaceutical uses are also disclosed. The compounds disclosed are useful, inter alia, as antagonists of opioid receptors.Type: ApplicationFiled: October 5, 2010Publication date: February 10, 2011Applicant: Adolor CorporationInventors: Bertrand Le Bourdonnec, Roland E. Dolle
-
Publication number: 20110028445Abstract: The present invention relates to compounds defined by formula (I) wherein the groups A, B, X, m, n and o are defined as in claim 1, possessing valuable pharmacological activity. Particularly the compounds are inhibitors of 11 ?-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme, such as metabolic diseases, in particular diabetes type 2, obesity and dyslipidemia.Type: ApplicationFiled: February 10, 2009Publication date: February 3, 2011Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Matthias Eckhardt, Frank Himmelsbach, Bradford S. Hamilton, Stefan Peters
-
Publication number: 20110014258Abstract: The present invention provides a coating comprising a bioactive material and an antimicrobial agent, wherein the concentration of said antimicrobial agent varies throughout the thickness of the coating.Type: ApplicationFiled: February 27, 2009Publication date: January 20, 2011Applicant: SMITH & NEPHEW, INC.Inventors: Lu Gan, Marcus L. Scott, Shilesh C. Jani, Laura S. Whitsitt
-
Publication number: 20100324080Abstract: The invention relates to Benzomorphan Compounds of Formula (I): wherein X, R1, R2, R3, R4, and R5 are as defined herein. These compounds are useful for treating constipation preferably constipation caused by mu-opioid agonist therapy.Type: ApplicationFiled: November 28, 2008Publication date: December 23, 2010Applicant: PURDUE PHARMA L.P.Inventor: Donald Kyle
-
Publication number: 20100311697Abstract: The present invention provides novel methods and compositions for the treatment and prevention of CNS-related conditions. One of the CNS-related conditions treated by the methods and compositions of the invention is Alzheimer's disease.Type: ApplicationFiled: April 2, 2010Publication date: December 9, 2010Applicant: Adamas Pharmaceuticals, Inc.Inventors: Gregory T. Went, Timothy J. Fultz
-
Publication number: 20100311782Abstract: Novel 3,4-disubstituted-4-(3-carbamoylphenyl)-piperidinylpropanoic acid compounds and their salts, including pharmaceutically acceptable salts, pharmaceutical compositions and methods of their use are disclosed. The novel compounds are useful, inter alia, as antagonists of opioid receptors.Type: ApplicationFiled: June 7, 2010Publication date: December 9, 2010Applicant: Adolor CorporationInventors: Roland E. Dolle, Bertrand Le Bourdonnec
-
Publication number: 20100291203Abstract: The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).Type: ApplicationFiled: May 24, 2010Publication date: November 18, 2010Applicant: PURDUE PHARMA L.P.Inventors: ROBERT F. KAIKO, Robert D. Colucci
-
Publication number: 20100286059Abstract: Embodiments of the invention provide methods of attenuating, e.g., inhibiting or reducing, cellular proliferation and migration, particularly endothelial cell proliferation and migration, including that associated with angiogenesis, as well as attenuating cancerous tumor growth and metastasis, using opioid antagonists, including, but not limited to, those that are peripherally restricted antagonists.Type: ApplicationFiled: March 12, 2010Publication date: November 11, 2010Inventors: Jonathan Moss, Mark Lingen, Patrick A. Singleton, Joe G.N. Garcia
-
Publication number: 20100249045Abstract: The present invention is in the field of oral, abuse resistant pharmaceutical compositions of opioid agonists, extended release pharmaceutical compositions of opioid agonists and extended release abuse resistant pharmaceutical compositions of opioid agonists and the use thereof. The present invention is also directed to extended release pharmaceutical compositions and the use thereof for preventing or minimizing the risk of abuse and/or toxicity from either intentional or unintentional tampering. The present invention is further directed at a method of preventing or minimizing the risk of abuse and/or toxicity from either intentional or unintentional tampering.Type: ApplicationFiled: April 26, 2008Publication date: September 30, 2010Applicant: THERAQUEST BIOSCIENCES, INC.Inventor: Najib Babul
-
Publication number: 20100240690Abstract: Compositions containing opioid antagonists, particularly alvimopan and its active metabolite, with improved solubility and bioavailability for oral or parenteral administration, injectable dosage formulations, kits, and methods of making and using same are disclosed. In preferred embodiments, invention provides injectable formulations containing opioid antagonists, particularly alvimopan and its active metabolite, having low solubility that may be readily prepared, are stable during storage, and provide maximum levels of opioid antagonists when administered parenterally, particularly via injection. The results are achieved by a combination of processing techniques and component selection.Type: ApplicationFiled: March 22, 2010Publication date: September 23, 2010Applicant: Adolor CorporationInventor: John D. Buehler
-
Publication number: 20100234416Abstract: Methods and compositions containing huperzine are used to prevent and alleviate neuropathic pain. The invention is also directed to methods and compositions for using huperzine for the prevention and/or treatment of neuropathic pain and orthostatic hypotension.Type: ApplicationFiled: May 13, 2010Publication date: September 16, 2010Inventor: Steven C. Schachter
-
Publication number: 20100227852Abstract: The invention relates to a novel drug combination therapy useful in the treatment of dementia comprising administering an 1-aminocyclohexane derivative such as memantine or neramexane and an acetylcholinesterase inhibitor (AChEI) such as galantamine, tacrine, donepezil, or rivastigmine.Type: ApplicationFiled: March 22, 2010Publication date: September 9, 2010Applicant: MERZ PHARMA GmbH & CO. KGaAInventor: Hans-Joerg Moebius
-
Publication number: 20100215590Abstract: The invention relates to a method for producing a micronized, virtually anhydrous form of (1?,2?,4?,5?,7?)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane bromide, said form per se, and the use thereof for producing a medicament, especially a medicament having an anticholinergic effect.Type: ApplicationFiled: December 7, 2006Publication date: August 26, 2010Applicant: Boehringer Ingelheim Pharma GmbH & Co. KGInventors: Norbert Rasenack, Mihael Walz, Michael Trunk, Hagen Graebner
-
Publication number: 20100190817Abstract: 8-Substituted-2,6-methano-3-benzazocines of general structure are useful as analgesics, anti-diarrheal agents, anticonvulsants, antitussives and anti-addiction medications.Type: ApplicationFiled: July 21, 2009Publication date: July 29, 2010Applicant: RENSSELAER POLYTECHNIC INSTITUTEInventor: Mark P. Wentland
-
Publication number: 20100172974Abstract: Bioavailable sustained release oral opioid analgesic dosage forms, comprising a plurality of multiparticulates produced via melt extrusion techniques are disclosed.Type: ApplicationFiled: March 12, 2010Publication date: July 8, 2010Inventors: Benjamin Oshlack, Mark Chasin, Hua-Pin Huang
-
Publication number: 20100130537Abstract: The invention provides methods for treating, preventing, and delaying the onset of dementia and mild cognitive impairments by administering to a patient in need thereof at least one cinnamide compound and one or more second-line active ingredients, such as cholinesterase inhibitors; AMPA receptor antagonists; NMDA receptor antagonists; and the like. The invention also provides pharmaceutical compositions, combinations, and kits.Type: ApplicationFiled: April 25, 2008Publication date: May 27, 2010Applicant: EISAI R&D MANAGEMENT CO., LTDInventor: Takehiko Miyagawa
-
Publication number: 20100105672Abstract: Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo by administering, in a therapeutic composition, are disclosed. Methods of preparing said conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of drug addiction, more particularly, cocaine addiction. Passive immunization using antibodies raised against conjugates of the instant invention is also disclosed. The therapeutic composition is suitable for co-therapy with other conventional drugs.Type: ApplicationFiled: August 3, 2009Publication date: April 29, 2010Inventors: Philip A. Swain, Victoria C. Schad, Julia L. Greenstein, Mark A. Exley, Barbara S. Fox, Stephen P. Powers
-
Publication number: 20100035854Abstract: A dry powder suitable for inhalation in a dry powder inhaler, the powder comprising a carrier, an active agent and at least 0.5% by weight of magnesium stearate, the powder being further characterized in that the less than 10% of the surface of the carrier material is covered with particles of magnesium stearate. The invention is also directed to a method of making dry powders by blending together the ingredients mentioned in a diffusion blender for a period time that is less than 60 minutes.Type: ApplicationFiled: August 6, 2009Publication date: February 11, 2010Inventors: Rudi Mueller-Walz, Roland Steiner